Andrii Shaliev led the development of an AI-native clinical trial management system for personalized cell therapy, demonstrating that AI can accelerate regulated software development by 70% while maintaining full FDA compliance. The platform manages 150+ patients and 2,400+ regulatory documents across distributed clinical sites, orchestrating the complete autologous cell therapy lifecycle.